Current Infectious Disease Reports

, Volume 14, Issue 3, pp 263–274 | Cite as

Chagas Disease in Non-Endemic Countries: Epidemiology, Clinical Presentation and Treatment

  • José A. Pérez-Molina
  • Francesca Norman
  • Rogelio López-Vélez
Tropical and Travel Medicine (LH Chen, Section Editor)

Abstract

Imported Chagas disease (Trypanosoma cruzi infection) is increasingly recognized as an emerging problem in the USA and Europe due to immigration from Latin America. Most migrants from endemic countries will have been infected during childhood. Based on the natural history of the disease, up to 35 % of those infected may develop cardiac and/or gastrointestinal manifestations during the third or fourth decade of life. This disease was described more than 100 years ago, yet many challenges still remain such as the identification of risk factors for visceral involvement, effective treatment for chronic cases, and reliable markers of cure following treatment. Transmission of the infection may occur even in non-endemic areas through non-vectorial routes and many countries are therefore currently facing the challenge of this emerging public health problem.

Keywords

Chagas disease Trypanosoma cruzi Neglected tropical diseases Polymerase chain reaction Benznidazole Nifurtimox Posaconazole 

Notes

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Organización Panamericana de la salud (OPS/OMS). Estimación cuantitativa de la Enfermedad de Chagas en las Américas. OPS/HDM/CD/425-06. Montevideo, Uruguay; 2006.Google Scholar
  2. 2.
    Bern C, Montgomery SP, Katz L, Caglioti S, Stramer SL. Chagas disease and the US blood supply. Curr Opin Infect Dis. 2008;21:476–82.PubMedCrossRefGoogle Scholar
  3. 3.
    Oliveira I, Torrico F, Munoz J, Gascon J. Congenital transmission of Chagas disease: a clinical approach. Expert Rev Anti Infect Ther. 2010;8:945–56.PubMedCrossRefGoogle Scholar
  4. 4.
    Albajar-Vinas P, Jannin J. The hidden Chagas disease burden in Europe. Euro Surveill; 2011, 16.Google Scholar
  5. 5.
    •• Bern C, Kjos S, Yabsley MJ, Montgomery SP. Trypanosoma cruzi and Chagas’ Disease in the United States. Clin Microbiol Rev. 2011;24:655–81. An excellent thorough review of the epidemiological, clinical and therapeutic aspects of Chagas disease in the USA.PubMedCrossRefGoogle Scholar
  6. 6.
    Basile L, Jansa J, Carlier Y, Salamanca D, Angheben A, Bartoloni A, et al. Chagas disease in European countries: the challenge of a surveillance system. Euro Surveill; 2011,16.Google Scholar
  7. 7.
    • Control and prevention of Chagas disease in Europe. Report of a WHO Informal Consultation (jointly organized by WHO headquarters and the WHO Regional Office for Europe). Geneva, Switzerland, 17––18 December 2009. WHO/HTM/NTD/IDM/2010.1. 2010. A detailed update on the epidemiology of Chagas disease in Europe. Includes useful recommendations on case detection and prevention. Google Scholar
  8. 8.
    Perez de Ayala A, Perez-Molina JA, Norman F, Lopez-Velez R. Chagasic cardiomyopathy in immigrants from Latin America to Spain. Emerg Infect Dis. 2009;15:607–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis. 2009;49:e52–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Verani JR, Montgomery SP, Schulkin J, Anderson B, Jones JL. Survey of obstetrician-gynecologists in the United States about Chagas disease. Am J Trop Med Hyg. 2010;83:891–5.PubMedCrossRefGoogle Scholar
  11. 11.
    •• Rassi Jr A, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375:1388–402. Excellent review of Chagas disease.PubMedCrossRefGoogle Scholar
  12. 12.
    Rassi Jr A, Rassi A, Little WC. Chagas’ heart disease. Clin Cardiol. 2000;23:883–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Maguire JH, Mott KE, Souza JA, Almeida EC, Ramos NB, Guimaraes AC. Electrocardiographic classification and abbreviated lead system for population-based studies of Chagas’ disease. Bull Pan Am Health Organ. 1982;16:47–58.PubMedGoogle Scholar
  14. 14.
    Viotti RJ, Vigliano C, Laucella S, Lococo B, Petti M, Bertocchi G, et al. Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart. 2004;90:655–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Pazin-Filho A, Romano MM, Almeida-Filho OC, Furuta MS, Viviani LF, Schmidt A, et al. Minor segmental wall motion abnormalities detected in patients with Chagas’ disease have adverse prognostic implications. Braz J Med Biol Res. 2006;39:483–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Gascon J, Albajar P, Canas E, Flores M, Gomez i Prat J, Herrera RN, et al. Diagnosis, management and treatment of chronic Chagas’ heart disease in areas where Trypanosoma cruzi infection is not endemic. Enferm Infecc Microbiol Clin. 2008;26:99–106.PubMedCrossRefGoogle Scholar
  17. 17.
    Hidron AI, Gilman RH, Justiniano J, Blackstock AJ, Lafuente C, Selum W, et al. Chagas cardiomyopathy in the context of the chronic disease transition. PLoS Negl Trop Dis. 2010;4:e688.PubMedCrossRefGoogle Scholar
  18. 18.
    Bern C, Montgomery SP, Herwaldt BL, Rassi Jr A, Marin-Neto JA, Dantas RO, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA. 2007;298:2171–81.PubMedCrossRefGoogle Scholar
  19. 19.
    Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. Ann Thorac Surg. 2001;71:1833–8.PubMedCrossRefGoogle Scholar
  20. 20.
    • Chin-Hong PV, Schwartz BS, Bern C, Montgomery SP, Kontak S, Kubak B, et al. Screening and treatment of chagas disease in organ transplant recipients in the United States: recommendations from the chagas in transplant working group. Am J Transplant. 2011;11:672–80. Updated guidelines on the management of Chagas disease in the context of transplantation in the USA. Evidence-based recommendations are made for donor screening, follow-up and treatment of organ recipients from infected donors.PubMedCrossRefGoogle Scholar
  21. 21.
    Riarte A, Luna C, Sabatiello R, Sinagra A, Schiavelli R, De Rissio A, et al. Chagas’ disease in patients with kidney transplants: 7 years of experience 1989–1996. Clin Infect Dis. 1999;29:561–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Diazgranados CA, Saavedra-Trujillo CH, Mantilla M, Valderrama SL, Alquichire C, Franco-Paredes C. Chagasic encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association. Lancet Infect Dis. 2009;9:324–30.PubMedCrossRefGoogle Scholar
  23. 23.
    • Perez-Molina JA, Rodriguez-Guardado A, Soriano A, Pinazo MJ, Carrilero B, Garcia-Rodriguez M, et al. Guidelines on the treatment of chronic coinfection by trypanosoma cruzi and HIV outside endemic areas. HIV Clin Trials. 2011;12:287–98. Updated guidelines on the diagnosis, treatment, and prevention of Chagas disease in patients coinfected with HIV in non-endemic countries for T. cruzi.PubMedCrossRefGoogle Scholar
  24. 24.
    Sartori AM, Ibrahim KY, Nunes Westphalen EV, Braz LM, Oliveira Jr OC, Gakiya E, et al. Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann Trop Med Parasitol. 2007;101:31–50.PubMedCrossRefGoogle Scholar
  25. 25.
    Flores-Chavez M, De Fuentes I, Gárate T, Cañavate C. Diagnóstico de laboratorio de la enfermedad de Chagas importada. Enferm Infecc Microbiol Clin. 2007;25(Supl 3):29–37.CrossRefGoogle Scholar
  26. 26.
    WHO Technical Report Series Nº 905. Control of Chagas Disease. Second report of the WHO Expert Committee. World Health Organization. Geneve; 2002.Google Scholar
  27. 27.
    • Brasil PE, De Castro L, Hasslocher-Moreno AM, Sangenis LH, Braga JU. ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis. BMC Infect Dis. 2010;10:337. Systematic review summarizing the performance of ELISA and PCR in the diagnosis of chronic Chagas disease.PubMedCrossRefGoogle Scholar
  28. 28.
    • Murcia L, Carrilero B, Munoz MJ, Iborra MA, Segovia M. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas’ disease: a prospective study in a non-disease-endemic country. J Antimicrob Chemother. 2010;65:1759–64. This prospective study evaluated antiparasitic therapy for chronic Chagas’ disease outside endemic areas as monitored by PCR. Although all patients showed negative results 90 days after therapy, 6.9 % of them had positive blood PCRs at the end of the follow-up period.PubMedCrossRefGoogle Scholar
  29. 29.
    Perez-Ayala A, Perez-Molina JA, Norman F, Navarro M, Monge-Maillo B, Diaz-Menendez M, et al. Chagas disease in Latin American migrants: a Spanish challenge. Clin Microbiol Infect. 2010.Google Scholar
  30. 30.
    Aguiar C, Batista AM, Pavan TB, Almeida EA, Guariento ME, Wanderley JS, Costa SC. Serological profiles and evaluation of parasitaemia by PCR and blood culture in individuals chronically infected by Trypanosoma cruzi treated with benzonidazole. Trop Med Int Health 2011.Google Scholar
  31. 31.
    Norman FF, Perez-Ayala A, Perez-Molina JA, Flores-Chavez M, Canavate C, Lopez-Velez R. Lack of association between blood-based detection of Trypanosoma cruzi DNA and cardiac involvement in a non-endemic area. Ann Trop Med Parasitol. 2011;105:425–30.PubMedCrossRefGoogle Scholar
  32. 32.
    •• Schijman AG, Bisio M, Orellana L, Sued M, Duffy T, Mejia Jaramillo AM, et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis. 2011;5:e931. This paper was the result of an international collaborative study among expert PCR laboratories from 16 countries, with the objective of launching an international validation of PCR procedures for detection of T. cruzi in human blood samples.PubMedCrossRefGoogle Scholar
  33. 33.
    • Bern C, Verastegui M, Gilman RH, Lafuente C, Galdos-Cardenas G, Calderon M, et al. Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia. Clin Infect Dis. 2009;49:1667–74. This study evaluated several techniques for the diagnosis of Trypanosoma cruzi congenital infections in Santa Cruz, Bolivia, highlighting the relevance of molecular methods for early detection in newborn.PubMedCrossRefGoogle Scholar
  34. 34.
    Benvenuti LA, Roggerio A, Coelho G, Fiorelli AI. Usefulness of qualitative polymerase chain reaction for Trypanosoma cruzi DNA in endomyocardial biopsy specimens of chagasic heart transplant patients. J Heart Lung Transplant. 2011;30:799–804.PubMedCrossRefGoogle Scholar
  35. 35.
    Sicuri E, Munoz J, Pinazo MJ, Posada E, Sanchez J, Alonso PL, Gascon J. Economic evaluation of Chagas disease screening of pregnant Latin American women and of their infants in a non endemic area. Acta Trop. 2011;118:110–17.PubMedCrossRefGoogle Scholar
  36. 36.
    Navarro M, Perez-Ayala A, Guionnet A, Perez-Molina JA, Navaza B, Estevez L, et al. Targeted screening and health education for Chagas disease tailored to at-risk migrants in Spain, 2007 to 2010. Euro Surveill 2011,16.Google Scholar
  37. 37.
    • Chappuis F, Mauris A, Holst M, Albajar-Vinas P, Jannin J, Luquetti AO, Jackson Y. Validation of a rapid immunochromatographic assay for diagnosis of Trypanosoma cruzi infection among Latin-American Migrants in Geneva, Switzerland. J Clin Microbiol. 2010;48:2948–52. A useful paper on the role of rapid diagnostic tests for T. cruzi infection in non-endemic countries. The main drawback of these tests would be their lack of sensitivity.PubMedCrossRefGoogle Scholar
  38. 38.
    Lopez-Chejade P, Roca C, Posada E, Pinazo MJ, Gascon J, Portus M. Utility of an immunochromatographic test for Chagas disease screening in primary healthcare. Enferm Infecc Microbiol Clin. 2010;28:169–71.PubMedCrossRefGoogle Scholar
  39. 39.
    Rodriques Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz. 2002;97:3–24.PubMedCrossRefGoogle Scholar
  40. 40.
    Castro JA, de Mecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas’ disease (American trypanosomiasis). Hum Exp Toxicol. 2006;25:471–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Wilkinson SR, Kelly JM. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev Mol Med. 2009;11:e31.PubMedCrossRefGoogle Scholar
  42. 42.
    • Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop. 2010;115:55–68. A comprenhensive review of current and future drugs for the treatment of T. cruzi infection.PubMedCrossRefGoogle Scholar
  43. 43.
    Le Loup G, Pialoux G, Lescure FX. Update in treatment of Chagas disease. Curr Opin Infect Dis. 2011;24:428–34.PubMedCrossRefGoogle Scholar
  44. 44.
    Raaflaub J, Ziegler WH. Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung. 1979;29:1611–14.PubMedGoogle Scholar
  45. 45.
    [Brazilian Consensus on Chagas disease]. Rev Soc Bras Med Trop. 2005;38(Suppl 3):7–29.Google Scholar
  46. 46.
    Coura JR, Borges-Pereira J. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem Inst Oswaldo Cruz. 2011;106:641–5.PubMedGoogle Scholar
  47. 47.
    • Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med. 2006;144:724–34. This non-randomized study compared the efficacy of benznidazole in a cohort of treated and non-treated patients with a long follow-up period, and demonstrated a reduced progression of Chagas disease among treated patients.PubMedGoogle Scholar
  48. 48.
    Ferreira RC, Ferreira LC. Mutagenicity of nifurtimox and benznidazole in the Salmonella/microsome assay. Braz J Med Biol Res. 1986;19:19–25.PubMedGoogle Scholar
  49. 49.
    de Toranzo EG, Masana M, Castro JA. Administration of benznidazole, a chemotherapeutic agent against Chagas disease, to pregnant rats. Covalent binding of reactive metabolites to fetal and maternal proteins. Arch Int Pharmacodyn Ther. 1984;272:17–23.PubMedGoogle Scholar
  50. 50.
    Coura JR, de Abreu LL, Willcox HP, Petana W. Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas’ disease, in a field area with interrupted transmission. I. Preliminary evaluation. Rev Soc Bras Med Trop. 1997;30:139–44.PubMedCrossRefGoogle Scholar
  51. 51.
    DNDi. New Child-Adapted Chagas Disease Treatment Approved for Registration. http://dndi.org/press-releases/1016-paedbenz.html (Last accessed February 10, 2012).
  52. 52.
    • Pinazo MJ, Munoz J, Posada E, Lopez-Chejade P, Gallego M, Ayala E, et al. Tolerance of benznidazole in treatment of chagas’ disease in adults. Antimicrob Agents Chemother. 2010;54:4896–9. A thorough description of the safety profile of benznidazole in a non-endemic country.PubMedCrossRefGoogle Scholar
  53. 53.
    Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertocchi G, Armenti A. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther. 2009;7:157–63.PubMedCrossRefGoogle Scholar
  54. 54.
    Cancado JR. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo. 2002;44:29–37.PubMedCrossRefGoogle Scholar
  55. 55.
    Gallerano RR, Sosa RR. Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy. Rev Fac Cien Med Univ Nac Cordoba. 2000;57:135–62.PubMedGoogle Scholar
  56. 56.
    Sosa-Estani S, Armenti A, Araujo G, Viotti R, Lococo B, Ruiz Vera B, et al. Treatment of Chagas disease with benznidazole and thioctic acid. Medicina (B Aires). 2004;64:1–6.Google Scholar
  57. 57.
    de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996;348:1407–13.PubMedCrossRefGoogle Scholar
  58. 58.
    Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am J Trop Med Hyg. 1998;59:526–9.PubMedGoogle Scholar
  59. 59.
    • Altcheh J, Moscatelli G, Moroni S, Garcia-Bournissen F, Freilij H. Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics. 2011;127:e212–18. A detailed description of benznidazole’s safety profile in the pediatric population.PubMedCrossRefGoogle Scholar
  60. 60.
    Escriba JM, Ponce E, Romero Ade D, Vinas PA, Marchiol A, Bassets G, et al. Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras. Mem Inst Oswaldo Cruz. 2009;104:986–91.PubMedCrossRefGoogle Scholar
  61. 61.
    Wegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas’ infection. Arzneimittelforschung. 1972;22:1624–35.PubMedGoogle Scholar
  62. 62.
    • Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin Infect Dis. 2010;51:e69–75. A comprehensive article on the safety profile of nifurtimox.PubMedCrossRefGoogle Scholar
  63. 63.
    Altcheh J, Biancardi M, Lapena A, Ballering G, Freilij H. Congenital Chagas disease: experience in the Hospital de Ninos, Ricardo Gutierrez, Buenos Aires, Argentina. Rev Soc Bras Med Trop. 2005;38 Suppl 2:41–5.PubMedGoogle Scholar
  64. 64.
    Levi GC, Lobo IM, Kallas EG, Amato Neto V. Etiological drug treatment of human infection by Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo. 1996;38:35–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Rassi A, Amato Neto V, de Siqueira AF, Ferriolli Filho F, Amato VS, Rassi GG, Rassi Junior A. Treatment of chronic Chagas’ disease with an association of nifurtimox and corticoid. Rev Soc Bras Med Trop. 2002;35:547–50.PubMedCrossRefGoogle Scholar
  66. 66.
    Burgos JM, Diez M, Vigliano C, Bisio M, Risso M, Duffy T, et al. Molecular identification of Trypanosoma cruzi discrete typing units in end-stage chronic Chagas heart disease and reactivation after heart transplantation. Clin Infect Dis. 2010;51:485–95.PubMedCrossRefGoogle Scholar
  67. 67.
    Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop. 2007;40:1–10.PubMedCrossRefGoogle Scholar
  68. 68.
    Ferreira Hde O. Treatment of the undetermined form of Chagas disease with nifortimox and benzonidazole. Rev Soc Bras Med Trop. 1990;23:209–11.PubMedGoogle Scholar
  69. 69.
    Viotti R, Vigliano C, Alvarez MG, Lococo B, Petti M, Bertocchi G, et al. Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease. PLoS Negl Trop Dis. 2011;5:e1314.PubMedCrossRefGoogle Scholar
  70. 70.
    •• Laucella SA, Mazliah DP, Bertocchi G, Alvarez MG, Cooley G, Viotti R, et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis. 2009;49:1675–84. This study explored early immunological markers of response after benznidazole therapy in patients with chronic Chagas disease, showing this drug has a substantial impact on parasite-specific immune responses.PubMedCrossRefGoogle Scholar
  71. 71.
    Schijman AG, Altcheh J, Burgos JM, Biancardi M, Bisio M, Levin MJ, Freilij H. Aetiological treatment of congenital Chagas’ disease diagnosed and monitored by the polymerase chain reaction. J Antimicrob Chemother. 2003;52:441–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Moya P, Basso B, Moretti E. Congenital Chagas disease in Cordoba, Argentina: epidemiological, clinical, diagnostic, and therapeutic aspects. Experience of 30 years of follow up. Rev Soc Bras Med Trop. 2005;38 Suppl 2:33–40.PubMedGoogle Scholar
  73. 73.
    Fernandes CD, Tiecher FM, Balbinot MM, Liarte DB, Scholl D, Steindel M, Romanha A. Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. Mem Inst Oswaldo Cruz. 2009;104:27–32.PubMedCrossRefGoogle Scholar
  74. 74.
    • Perez-Molina JA, Perez-Ayala A, Moreno S, Fernandez-Gonzalez MC, Zamora J, Lopez-Velez R. Use of benznidazole to treat chronic Chagas’ disease: a systematic review with a meta-analysis. J Antimicrob Chemother. 2009;64:1139–47. A review of the efficacy of benznidazole in the treatment of chronic Chagas disease.PubMedCrossRefGoogle Scholar
  75. 75.
    Reyes PA, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev. 2005:CD004102.Google Scholar
  76. 76.
    Marin-Neto JA, Rassi Jr A, Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S, et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas’ cardiomyopathy: the BENznidazole evaluation for interrupting trypanosomiasis (BENEFIT). Am Heart J. 2008;156:37–43.PubMedCrossRefGoogle Scholar
  77. 77.
    Bustamante JM, Bixby LM, Tarleton RL. Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med. 2008;14:542–50.PubMedCrossRefGoogle Scholar
  78. 78.
    Garcia S, Ramos CO, Senra JF, Vilas-Boas F, Rodrigues MM, Campos-de-Carvalho AC, et al. Treatment with benznidazole during the chronic phase of experimental Chagas’ disease decreases cardiac alterations. Antimicrob Agents Chemother. 2005;49:1521–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Bisio M, Cura C, Duffy T, Altcheh J, Giganti S, Begher S, et al. Trypanosoma cruzi discrete typing units in Chagas disease patients with HIV co-infection. Rev Biomed. 2009;20:166–78.CrossRefGoogle Scholar
  80. 80.
    Sosa-Estani S, Cura E, Velazquez E, Yampotis C, Segura EL. Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission. Rev Soc Bras Med Trop. 2009;42:484–7.PubMedCrossRefGoogle Scholar
  81. 81.
    •• Brutus L, Castillo H, Bernal C, Salas NA, Schneider D, Santalla JA, Chippaux JP. Detectable Trypanosoma cruzi parasitemia during pregnancy and delivery as a risk factor for congenital Chagas disease. Am J Trop Med Hyg. 2010;83:1044–7. This study demonstrated a high proportion of parasitemia in infected pregnant women (28.6 %) that its prevalence increased during the third trimester, and decreased at delivery. The likelihood of congenital infection was significantly correlated with parasite density in the mother’s blood.PubMedCrossRefGoogle Scholar
  82. 82.
    Buckner FS, Navabi N. Advances in Chagas disease drug development: 2009–2010. Curr Opin Infect Dis. 2010;23:609–16.PubMedCrossRefGoogle Scholar
  83. 83.
    Olivieri BP, Molina JT, de Castro SL, Pereira MC, Calvet CM, Urbina JA, Araujo-Jorge TC. A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease. Int J Antimicrob Agents. 2010;36:79–83.PubMedCrossRefGoogle Scholar
  84. 84.
    Pinazo MJ, Espinosa G, Gallego M, Lopez-Chejade PL, Urbina JA, Gascon J. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg. 2010;82:583–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Noxafil (Posaconazole). Summary of product characteristics. Merck Sharp & Dohme Ltd Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom. In.Google Scholar
  86. 86.
    Diniz Lde F, Caldas IS, Guedes PM, Crepalde G, de Lana M, Carneiro CM, et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob Agents Chemother. 2010;54:2979–86.PubMedCrossRefGoogle Scholar
  87. 87.
    Cencig S, Coltel N, Truyens C, Carlier Y. Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome. PLoS Negl Trop Dis. 5:e1216.Google Scholar
  88. 88.
    Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1–207.Google Scholar
  89. 89.
    Pinazo MJ, Miranda B, Rodriguez-Villar C, Altclas J, Brunet Serra M, Garcia-Otero EC, et al. Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. Transplant Rev (Orlando). 2011;25:91–101.CrossRefGoogle Scholar
  90. 90.
    Fontes Rezende RE, Lescano MA, Zambelli Ramalho LN, de Castro Figueiredo JF, Oliveira Dantas R, Garzella Meneghelli U, Pimenta Modena JL. Reactivation of Chagas’ disease in a patient with non-Hodgkin’s lymphoma: gastric, oesophageal and laryngeal involvement. Trans R Soc Trop Med Hyg. 2006;100:74–8.PubMedCrossRefGoogle Scholar
  91. 91.
    Metze K, Lorand-Metze I, De Almeida EA, De Moraes SL. Reactivation of Chagas’ myocarditis during therapy of Hodgkin’s disease. Trop Geogr Med. 1991;43:228–30.PubMedGoogle Scholar
  92. 92.
    Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, et al. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLoS Negl Trop Dis. 2009;3:e488.PubMedCrossRefGoogle Scholar
  93. 93.
    Villarreal D, Nirde P, Hide M, Barnabe C, Tibayrenc M. Differential gene expression in benznidazole-resistant Trypanosoma cruzi parasites. Antimicrob Agents Chemother. 2005;49:2701–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Moreno M, D’Avila DA, Silva MN, Galvao LM, Macedo AM, Chiari E, et al. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease. Mem Inst Oswaldo Cruz. 2012;105:918–24.CrossRefGoogle Scholar
  95. 95.
    Rassi Jr A, Rassi A, Marin-Neto JA. Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Mem Inst Oswaldo Cruz. 2009;104 Suppl 1:152–8.PubMedCrossRefGoogle Scholar
  96. 96.
    • Rassi Jr A, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and validation of a risk score for predicting death in Chagas’ heart disease. N Engl J Med. 2006;355:799–808. A simple risk score to predict death in patients with Chagas’ heart disease.PubMedCrossRefGoogle Scholar
  97. 97.
    Pinto Dias JC. The treatment of Chagas disease (South American trypanosomiasis). Ann Intern Med. 2006;144:772–4.PubMedGoogle Scholar
  98. 98.
    Viotti R, Vigliano C, Lococo B, Petti M, Bertocchi G, Alvarez MG, Armenti A. Clinical predictors of chronic chagasic myocarditis progression. Rev Esp Cardiol. 2005;58:1037–44.PubMedCrossRefGoogle Scholar
  99. 99.
    • Barros ML, Ribeiro A, Nunes Mdo C, Rocha MO. Association between left ventricular wall motion abnormalities and ventricular arrhythmia in the indeterminate form of Chagas disease. Rev Soc Bras Med Trop. 2011;44:213–16.PubMedCrossRefGoogle Scholar
  100. 100.
    Rassi Jr A, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation. 2007;115:1101–8. This systematic review identified that impaired left ventricular function, New York Heart Association class III/IV, cardiomegaly, and non-sustained ventricular tachycardia were related to poor prognosis in patients with chronic Chagas disease.PubMedCrossRefGoogle Scholar
  101. 101.
    Oliveira-Filho J, Viana LC, Vieira-de-Melo RM, Faical F, Torreao JA, Villar FA, Reis FJ. Chagas disease is an independent risk factor for stroke: baseline characteristics of a Chagas disease cohort. Stroke. 2005;36:2015–17.PubMedCrossRefGoogle Scholar
  102. 102.
    Carod-Artal FJ, Gascon J. Chagas disease and stroke. Lancet Neurol. 2010;9:533–42.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • José A. Pérez-Molina
    • 1
  • Francesca Norman
    • 1
  • Rogelio López-Vélez
    • 1
  1. 1.Tropical Medicine, Infectious Diseases DepartmentHospital Universitario Ramón y Cajal, IRYCISMadridSpain

Personalised recommendations